Argos Therapeutics (OTCMKTS:ARGSQ) and Synaptogenix (NASDAQ:TAOX) Head-To-Head Comparison

Argos Therapeutics (OTCMKTS:ARGSQ) and Synaptogenix (NASDAQ:TAOX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Argos Therapeutics and Synaptogenix, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Argos Therapeutics	0	0	0	0	0.00
Synaptogenix	1	0	0	0	1.00

Earnings & Valuation

This table compares Argos Therapeutics and Synaptogenix”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Argos Therapeutics	$1.90 million	0.30	-$40.57 million	N/A	N/A
Synaptogenix	$300,000.00	94.87	-$28.74 million	($13.28)	-0.29

Synaptogenix has lower revenue, but higher earnings than Argos Therapeutics.

Profitability

This table compares Argos Therapeutics and Synaptogenix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Argos Therapeutics	N/A	N/A	N/A
Synaptogenix	N/A	-163.40%	-133.47%

Institutional & Insider Ownership

10.3% of Synaptogenix shares are held by institutional investors. 28.2% of Argos Therapeutics shares are held by insiders. Comparatively, 2.7% of Synaptogenix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Argos Therapeutics has a beta of 2.47, indicating that its share price is 147% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Summary

Argos Therapeutics beats Synaptogenix on 5 of the 9 factors compared between the two stocks.

About Argos Therapeutics

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.